Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26008895 | 0.87 | CNR1 (0.40) | MAPK14PTGDR2HDAC3HDAC1HDAC10 | |
| SCHEMBL798842 | 0.85 | GAA (0.49) | MAPK14PTGDR2PTGER1GAABRD9 | |
| SCHEMBL19271750 | 0.83 | MAPK14 (0.47) | MAPK14HDAC3HDAC1LCKCYP17A1 | |
| SCHEMBL26003573 | 0.83 | MAPK14 (0.36) | MAPK14PTGDR2HDAC3HDAC1HDAC10 | |
| SCHEMBL25594883 | 0.83 | MAPK14 (0.39) | MAPK14PTGDR2HDAC3HDAC1HDAC10 | |
| SCHEMBL172126 | 0.82 | MAPK14 (0.39) | MAPK14PTGDR2HDAC3HDAC1HDAC10 | |
| SCHEMBL28626032 | 0.79 | ABCB1 (0.38) | MAPK14PTGDR2PTGER1GAA | |
| SCHEMBL24035217 | 0.79 | MAPK14 (0.39) | MAPK14PTGDR2HDAC3HDAC1PTGER1 | |
| SCHEMBL26733944 | 0.77 | KCNJ6 (0.45) | MAPK14PTGDR2 | |
| SCHEMBL27528629 | 0.74 | PTGDR2 (0.35) | MAPK14PTGDR2HDAC3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2020123453-A2 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | MAPK14 1090/4885PTGDR2 3256/4885HDAC3 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.